Navigation Links
Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device
Date:12/8/2010

in and allows for on-demand bolus dosing around mealtimes thereby providing an alternative to taking multiple daily insulin injections.

The V-Go is engineered to simplify basal-bolus insulin therapy for the millions of people suffering from Type 2 diabetes. The V-Go is small, lightweight, and worn under the patients' clothing. It measures just 2.4 x 1.3 x 0.5 inches and weighs approximately 1 ounce when filled with insulin. Patients apply a new V-Go to the skin daily for one 24-hour period. The V-Go is not electronic, making it easy to operate and use.

About Valeritas, Inc.

Valeritas is a medical technology company committed to the development and commercialization of innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes.  The Valeritas medical technologies portfolio is headlined by the h-Patch™ technology. The V-Go Disposable Insulin Delivery Device, designed for the simple delivery of basal-bolus insulin therapy via a preset basal rate and on-demand bolus dosing around mealtimes, is the first use of the h-Patch™ technology.

In addition to the V-Go, the Valeritas delivery technology portfolio includes the

h-Patch™ for the delivery of other compounds in addition to insulin, the Mini-Ject™ Pre-Filled Needle-Free Delivery System, and the Micro-Trans™ Microneedle Delivery System.  These technologies, when combined with certain compounds, are designed to enhance the delivery of a variety of injectable drugs resulting in improved patient acceptance and outcomes.

Headquartered in Bridgewater, NJ, Valeritas operates its R&D and manufacturing in a state-of-the-art facility in Shrewsbury, MA. Valeritas' primary investors include MPM Capital, Pitango Venture Capital, Abingworth, US Venture Partners, ONSET Ventures, ATV Capital, HLM Venture Partners, CHL Medical Partners, Kaiser P
'/>"/>

SOURCE Valeritas LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
2. Caliper Continues Participation in EPAs Expanded ToxCast Program; Receives Remaining Phase II Compounds for Screening in Fourth Quarter
3. Varespladib Receives 2010 European Society Pediatric Research Award
4. QuantaLife, Inc. Receives Tax Credit for Development of Droplet Digital™ PCR
5. Caraco Receives Sun Pharma Proposal to Purchase All Outstanding Shares
6. Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
7. Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy
8. Palatin Technologies Receives Non-Compliance Letter from NYSE Amex
9. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
10. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
11. Neuro Kinetics Receives HHS Therapeutic Discovery Grant to Further Research Into Early Diagnosis of Sports Concussions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 The Wolf Administration today ... Pennsylvania State Police and local ... naloxone. Heroin and opioid overdose are the ... , killing more individuals than those involved in ... died from a drug overdose. " ...
(Date:8/31/2015)... Aug. 31, 2015  Dipexium Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of Locilex® (pexiganan cream 0.8%), a ... to participate in four investor conferences in September. ... the Sidoti & Company, LLC Emerging Growth Conference ... David P. Luci , President & Chief Executive Officer, ...
(Date:8/31/2015)... , August 31, 2015 ... BOLT, OTCQX: BLGTY) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, today announced ... MCTC), has identified several new genetic markers with ... in patients treated with bisphosphonate drugs and was ...
Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4
... June 21, 2010 ReportsandReports announces it Will,Carry Cardiovascular Devices Market ... , , ... http://www.reportsandreports.com/market-reports/netherlands-cardiovascular-de ,vices-market-outlook-to-2016/) , , , ... (Due to the length of these URLs, it may be necessary to copy ...
... AHMEDABAD, India , June 21, 2010 ... healthcare companies has,received Phase I clinical trial permission from the DCGI for ... Centre using a,unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule. ... ...
Cached Medicine Technology:Cardiovascular Devices Market Outlook June Update by ReportsandReports 2Cardiovascular Devices Market Outlook June Update by ReportsandReports 3Cardiovascular Devices Market Outlook June Update by ReportsandReports 4Cardiovascular Devices Market Outlook June Update by ReportsandReports 5Cardiovascular Devices Market Outlook June Update by ReportsandReports 6Cardiovascular Devices Market Outlook June Update by ReportsandReports 7Cardiovascular Devices Market Outlook June Update by ReportsandReports 8Cardiovascular Devices Market Outlook June Update by ReportsandReports 9Cardiovascular Devices Market Outlook June Update by ReportsandReports 10Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 2Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 3
(Date:8/31/2015)... , ... August 31, 2015 , ... ... Surgery Program at Monmouth, was one of the first doctors in the area ... of this new approach have been impressive: faster recovery, decreased immediate and long-term ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... With the FCPX LUT Soft pack from ... LUT is a Lookup Table that contains a mathematical formula for modifying an image. The ... comes with 60 soft CUBE LUT files. , FCPX LUT Soft requires Final Cut ...
(Date:8/31/2015)... ... August 31, 2015 , ... Diablo ... announced today that it has officially launched a new website and company identity ... brand refresh are more closely aligned with the company’s strategic vision for growth ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dad Phil, son ... ceremony on Aug. 26, generously hosted by the Collinsville Chamber of Commerce, but ... National Call Center and website since Aug. 17. , The Greens have operated ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... provider of the CME-certified annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for ... be held Nov. 4 – 6 in New York City. The annual legacy ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4
... Almac ... on academically based clinical trials. , ... (PRWEB) May 5, 2010 -- The site in Durham which recently doubled capacity ... part of the Duke Clinical Research Institute from 1990-2000 with all of the studies handled ...
... whose spouse has dementia are at significantly higher risk ... adults whose spouse never develops dementia. This is ... the Journal of the American Geriatrics Society . ... natural marital obligation, and spousal caregivers often report positive ...
... ,numerous deficiencies, at plant , TUESDAY, May 4 ... in ingredients used to make the liquid cold and ... drug giant McNeil Consumer Healthcare, according to a report ... Administration. , Last Friday, McNeil initiated a voluntary recall ...
... ... quinoa, and teff provide important nutrients for the gluten-free diet, but Carol Fenster bakes with ... pastries. To celebrate May as National Celiac Awareness month, she offers a free sorghum-based cookbook, ... . , ...
... stroke , TUESDAY, May 4 (HealthDay News) -- Being ... attack or stroke in men older than 45, a new ... ages 45 to 69, who enrolled in the California Men,s ... followed until Dec. 31, 2007. , During the follow-up, there ...
... - Reasonable worst-case scenarios for global warming could lead ... to research findings from Purdue University and the University ... first time have calculated the highest tolerable "wet-bulb" temperature ... the first time in human history in future climate ...
Cached Medicine News:Health News:Almac's North Carolina Facility Continues Growth in Academically Based Clinical Trials 2Health News:Spouses of dementia sufferers have a 6-fold increased risk of dementia onset 2Health News:FDA Found Bacteria in Ingredients for Recalled Tylenol, Benadryl 2Health News:Carol Fenster Offers Tips for Gluten-Free Cooking with Sorghum: May is National Celiac Awareness Month 2Health News:Researchers find future temperatures could exceed livable limits 2Health News:Researchers find future temperatures could exceed livable limits 3
... (PTH) is synthesized by the parathyroid ... to decreased extracellular calcium concentrations. PTH ... and decreasing calcium excretion by the ... intact PTH is rapidly degraded into ...
ACTIVATED CLOTTING TIME SYSTEM...
... Erythropoietin (EPO) is the primary known ... The predicted molecular weight of human EPO ... circulating form of EPO has an estimated ... itself appears to have a unique structure, ...
... versatility. Positron Corporation is the exclusive distributor ... whole body PET scanners. This unique performance ... quality images in clinical oncology, cardiology, and ... only scanner on the market that is ...
Medicine Products: